United Kingdom· GB-APID-16522711000001107
NovoRapid Penfill 100units/ml solution for injection 3ml cartridges
A medicinal product containing insulin aspart, registered in United Kingdom by Mawdsley-Brooks & Company Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Insulin aspart
- Manufacturer
- Mawdsley-Brooks & Company Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin aspart in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United States.Insulin Aspart Protamine and Insulin AspartA-S Medication Solutions
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- IrelandDazparda 100 units/ml solution for injection in pre-filled penGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d3a0d25b-aa39-4b67-ad5d-8683636dc572 GET /v1/drugs/d3a0d25b-aa39-4b67-ad5d-8683636dc572?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "16522711000001107",
"desc": "NovoRapid Penfill 100units/ml solution for injection 3ml cartridges (Mawdsley-Brooks & Company Ltd)",
"form": "Solution for injection",
"vpid": "3468611000001108",
"source": "dmd",
"vtm_id": "776338003",
"strength": "100 unit",
"substance": "Insulin aspart",
"ingredient": "Insulin aspart",
"supplier_code": "15125811000001100"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.